2 Penny Stocks That Have Upside Massive Potential Right Now!
27 Setembro 2021 - 6:10AM
Finscreener.org
There are several strategies that
investors employ to beat the broader markets. One such strategy
that can be considered high-risk is to invest in penny stocks.
Generally, stocks trading below $5 are defined as penny stocks.
These lower-priced companies offer investors an attractive
risk/reward combination that can help them outpace index
returns.
The Finscreener penny stocks dashboard
provides you with a list of
companies that can be added to your watchlist. But here, we look at
two penny stocks that are backed by Wall Street analysts so that
you can make an informed investment decision. Both the stocks have
significant upside potential at current prices.
A micro-cap penny stock in electroCore
Valued at a market cap of less
than $100 million, electroCore (NASDAQ:
ECOR) is a
commercial-stage medical device company. Its engaged in the
development and commercialization of a range of non-invasive vagus
nerve stimulation or nVNS therapies. Its developing gammaCore which
is a prescription only nVNS therapy for the treatment of pain
associated with migraine and episodic cluster headaches in adults.
The company’s flagship product is gammaCore Sapphire which is a
rechargeable and reloadable handheld delivery system for multi-year
use.
Right now, electroCore is
involved in the investigation of nerve treatments related to
nervous system disorders such as PTSD and Parkinson’s. In August
2021, it published a pilot study that indicated vagus nerve
stimulation lowered inflammatory response to stress in PTSD
patients.
In the second quarter of 2021,
electroCore’s revenue stood at $1.3 million which was 69% higher
than the year-ago period. Its sales are forecast to rise by 66.2%
to $5.81 million in 2021 and by 74.7% to $10.15 million in 2022.
The company’s sales stood at just $811,000 in 2017.
A majority of electroCore’s sales
are driven due to its contract with the Department of Veterans
Affairs which results in stable revenue. This market is relatively
untapped and remains a key revenue driver for the firm. Further,
electroCore is planning to expand its suite of solutions to include
treatments for other neurological disorders.
Analysts tracking the stock
expect it to gain more than 200% in the next 12-months.
Accuray Inc. is a top small-cap stock
Accuray Inc. (NASDAQ:
ARAY) has a market cap of
$353 million and the stock is down 31% in the last five years. It
develops, manufactures, and sells radiotherapy systems for
alternative cancer treatments. The company’s CyberKnife System is a
robotic stereotactic radiosurgery and stereotactic body radiation
therapy system used for the treatment of various types of cancer
and tumors in the body, such as prostate, lung, brain, spine,
liver, pancreas, and kidney.
Its portfolio of products is
marketed directly to customers via sales agents and group
purchasing organizations in the U.S. In the fiscal fourth quarter
of 2021 that ended in June, Accuray’s sales rose 17% year over year
to $111 million. Its gross orders also grew 19% to $112.7 million,
allowing the company to end the year with a backlog of $616.4
million.
Accuray confirmed that
trade-ins/trade-ups accounted for 27% of global orders as bookings
were robust across regions including the Americas, Asia-Pacific,
Europe and the Middle East. Analysts expect sales to rise by 4.9% to $415.82 million in 2021 and by 6% to
$441 million in 2022. Its adjusted earnings per share are also
forecast to rise from $0.04 in 2020 to $0.11 in 2021.
Accuray stock is currently
trading at $3.89 which is significantly lower than its 12-month
average price target of $8.20.
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024